WuXi AppTec Co., Ltd. (WUXIF) Q2 2025 Earnings Call Transcript

WuXi AppTec reported robust Q2 and H1 2025 financial results, with first-half total revenue reaching RMB 20.80 billion and adjusted non-IFRS net profit surging 44.4% year-over-year to RMB 6.31 billion, driven by strong execution, new capacity ramp-up, and significant growth in its WuXi Chemistry and TIDES segments, particularly from late-stage clinical and commercial projects like oral GLP-1. This strong performance led the company to raise its full-year revenue growth guidance to 13-17% and anticipate further margin improvement, while committing substantial capital to global expansion and shareholder returns. The firm emphasized its successful CRDMO business model, strong U.S. revenue growth, and the positive impact of China's biopharma out-licensing trends, despite ongoing challenges in early-stage biotech funding.

Analysis

WuXi AppTec delivered a robust first half for 2025, significantly outperforming consensus estimates and leading to an upward revision of its full-year revenue growth guidance to a range of 13% to 17%. The strong performance was primarily driven by the WuXi Chemistry (CRDMO) segment, which saw revenue climb 33.5% year-over-year to RMB 16.3 billion. Within this, the TIDES new modality business was a standout, with revenue surging 141% to RMB 5.03 billion, largely propelled by late-stage and commercial GLP-1 projects. This operational momentum, which management attributes to efficient execution and faster-than-expected capacity ramp-up, also boosted profitability; adjusted non-IFRS net profit grew 44.4% to RMB 6.31 billion, with the corresponding margin expanding to 30.4%. The company's future revenue visibility is supported by a record backlog for continuing operations, which grew 37.2% to RMB 56.69 billion. In contrast, the WuXi Testing and WuXi Biology segments faced headwinds from market pricing pressures, resulting in a slight revenue decline and modest growth, respectively. Geographically, revenue from U.S.-based companies was a key strength, growing 38.4%, while management noted that the strong H1 results imply a moderation to near double-digit growth in H2 due to a high comparative base and capacity utilization nearing its peak. The company is simultaneously pursuing aggressive global expansion, with a planned capex of RMB 7-8 billion, and substantial shareholder returns, including nearly RMB 7 billion in dividends and buybacks.

Key Decisions for Investors

• Investors should focus on the sustained momentum in the high-margin CRDMO business, particularly the TIDES segment, as this is the primary driver of the upgraded revenue and profit guidance, with management projecting approximately 80% growth for TIDES for the full year.
• Be mindful of the implied growth moderation in the second half of the year, which management attributes to a high 2024 comparative base and capacity constraints, and note the persistent pricing pressure impacting the WuXi Testing and Biology segments.
• Evaluate the company's aggressive capital allocation, which balances a RMB 7-8 billion capex plan for global expansion with nearly RMB 7 billion in shareholder returns, while remaining vigilant about external risks such as potential U.S. dollar depreciation and any shifts in customer behavior related to global trade tariffs.